Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest & Investment Income: 2011-2025

Historic Interest & Investment Income for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $9.4 million.

  • Enanta Pharmaceuticals' Interest & Investment Income fell 34.95% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 36.07%. This contributed to the annual value of $9.4 million for FY2025, which is 36.07% down from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Interest & Investment Income is $9.4 million, which was down 36.07% from $14.8 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Interest & Investment Income high stood at $14.8 million for FY2024, and its period low was $1.6 million during FY2022.
  • Moreover, its 3-year median value for Interest & Investment Income was $11.4 million (2023), whereas its average is $11.9 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Interest & Investment Income slumped by 68.77% in 2021, and later surged by 622.19% in 2023.
  • Enanta Pharmaceuticals' Interest & Investment Income (Yearly) stood at $2.0 million in 2021, then dropped by 22.17% to $1.6 million in 2022, then skyrocketed by 622.19% to $11.4 million in 2023, then surged by 30.02% to $14.8 million in 2024, then slumped by 36.07% to $9.4 million in 2025.